The Enzyme Experts
0
0
Resources
Company
Contact
X

Essential insights based on 3rd party publications:

Get the White Paper now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X

Quantification Challenges of Chromatin — Associated Host Cell DNA:
An Underestimated Risk

  • Discover why host cell DNA quantities are often significantly underestimated.
  • Understand the limitation of conventional nucleases when degrading chromatin

Download the poster here
and get access to the
interactive Q&A

Get the Poster now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X

The Largest Overlooked Cost Driver in Viral Vector Production

  • Up to half of produced vector is lost during Down Stream Processing(DSP)
  • The majority of manufacturing cost accumulates is DSP raw materials
  • Nuclease design decisions determine downstream economics

Download here and get access to the interactive Q&A

Get the Poster now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Investors News

ArcticZymes' M-SAN HQ Sets New Standard for Measles Virus Purification with Unmatched DNA Clearance & High Recovery Rates

Nov 21, 2024

Tromsø, Norway – November 21, 2024 – ArcticZymes Technologies ASA (OSE: AZT), is proud to highlight the exceptional performance of our M-SAN HQ nuclease in the purification of recombinant measles viruses (MV), as detailed in a recent publication in the Journal of Chromatography A.

Read More
Read More

ArcticZymes Technologies Announces Commercial Strategic Transformation and Q3 2024 Financial Results

Nov 6, 2024

Tromsø, Norway, November 6th, 2024 – ArcticZymes Technologies (OSE: AZT) reported revenues of NOK 24.1 million and an EBITDA of NOK -2.3 million for the third quarter of 2024.

Read More
Read More

ArcticZymes Highlights Industry-Leading Success at ESGCT 2024

Oct 24, 2024

ArcticZymes Technologies ASA (OSE: AZT), a global leader in enzyme innovation for bioprocessing, is excited to unveil breakthrough developments presented at the prestigious European Society of Gene and Cell Therapy (ESGCT) 2024 conference

Read More
Read More

ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing

Sep 17, 2024

ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing

Read More
Read More